Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

Atezolizumab for treating untreated locally advanced or metastatic urothelial carcinoma is recommended by NICE

Published: 14 December 2017
Patient having chemotherapy
Urothelial cancer most commonly affects the bladder

The National Institute for Health and Care Excellence (NICE) has issued guidance to the national health service on the use of the drug Atezolizumab (Tecentriq®) informed by a report produced by SHTAC.

NICE’s guidance recommends atezolizumab for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults, for whom cisplatin-based chemotherapy is unsuitable, only if the conditions of the managed access agreement for atezolizumab are followed.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research into cancer please visit our Research page.


Privacy Settings